261
Views
8
CrossRef citations to date
0
Altmetric
Research Articles

Computational screening and MM/GBSA-based MD simulation studies reveal the high binding potential of FDA-approved drugs against Cutibacterium acnes sialidase

ORCID Icon, ORCID Icon, ORCID Icon & ORCID Icon
Pages 6245-6255 | Received 21 Mar 2023, Accepted 29 Jun 2023, Published online: 07 Aug 2023

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Mohammed Ageeli Hakami, Ali Hazazi, Mishal Olayan Alsulami & Ahad Amer Alsaiari. Mitoxantrone 2HCl’s adroit activity against cervical cancer replication and maintenance proteins: a multitargeted approach. Journal of Biomolecular Structure and Dynamics 0:0, pages 1-14.
Read now
Hussam Murad & Misbahudin Rafeeq. Cheminformatics approach for identification of N-HyMenatPimeMelly as a novel potential ligand against RAS and renal chloride channel. Journal of Biomolecular Structure and Dynamics 0:0, pages 1-15.
Read now

Articles from other publishers (6)

Mohammed Ali Alshehri, Saeed A. Asiri, Nawal Helmi, Hanadi M. Baeissa, Abdullah Hamadi, Abdulrahman Alzahrani, Rashed Mohammed Alghamdi, Misbahuddin M. Rafeeq, Zeyad M. Alharbi & Mohammad Azhar Kamal. (2024) Unrevealing the multitargeted potency of 3-1-BCMIYPPA against lung cancer structural maintenance and suppression proteins through pharmacokinetics, QM-DFT, and multiscale MD simulation studies. PLOS ONE 19:6, pages e0303784.
Crossref
Abdulkarim S. Binshaya, Omar Saad Alkahtani, Fahad M. Aldakheel, Ahmed Hjazi & Hassan H. Almasoudi. (2024) Structure-based multitargeted docking screening, pharmacokinetics, DFT, and dynamics simulation studies reveal mitoglitazone as a potent inhibitor of cellular survival and stress response proteins of lung cancer. Medical Oncology 41:5.
Crossref
Hassan Hussain Almasoudi, Mutaib M. Mashraqi, Saleh A. Alshamrani, Afaf Awwadh Alharthi, Ohud Alsalmi, Mohammed H. Nahari, Fares Saeed H. Al-Mansour & Abdulfattah Yahya M. Alhazmi. (2024) Structure-Based In Silico Approaches Reveal IRESSA as a Multitargeted Breast Cancer Regulatory, Signalling, and Receptor Protein Inhibitor. Pharmaceuticals 17:2, pages 208.
Crossref
Mohammed Ageeli Hakami, Ali Hazazi, Fawaz Albloui, Amal F. Gharib, Fouzeyyah Ali Alsaeedi, Osama Abdulaziz, Abdulfattah Y. Alhazmi & Ahad Amer Alsaiari. (2024) Delineated 3-1-BenCarMethInYlPro-Phosphonic Acid’s Adroit Activity against Lung Cancer through Multitargeted Docking, MM\GBSA, QM-DFT and Multiscale Simulations. International Journal of Molecular Sciences 25:1, pages 592.
Crossref
Hassan Hussain Almasoudi, Mohammed H. Nahari, Abdulfattah Yahya M. Alhazmi, Saleh Hussain A. Almasabi, Fares Saeed H. Al-Mansour & Mohammed Ageeli Hakami. (2023) Delineating Pixantrone Maleate’s adroit activity against cervical cancer proteins through multitargeted docking-based MM\GBSA, QM-DFT and MD simulation. PLOS ONE 18:12, pages e0295714.
Crossref
Mohammed Ali Alshehri, Saeed Ahmed Asiri, Abdulrahman Alzahrani, Reem S. Alazragi, Leena S. Alqahtani, Amany I. Alqosaibi, Mashael M. Alnamshan, Qamre Alam & Misbahuddin M. Rafeeq. (2023) Multitargeted inhibitory effect of Mitoxantrone 2HCl on cervical cancer cell cycle regulatory proteins: a multitargeted docking-based MM\GBSA and MD simulation study. Medical Oncology 40:11.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.